Apr 30 |
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
|
Apr 30 |
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
|
Apr 25 |
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
|
Apr 22 |
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
|
Apr 16 |
As more rare disease therapies launch, their prices are rising
|
Apr 16 |
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
|
Apr 15 |
Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
|
Apr 15 |
Ultragenyx reports serious adverse effects in gene therapy trial
|
Apr 15 |
Ultragenyx says Angelman therapy is working, but safety questions remain
|
Apr 15 |
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
|